Why Do Breast Implants Get Hard and What to Do

Breast implants get hard because the body builds a tight shell of scar tissue around them, a process called capsular contracture. Every implant triggers some degree of capsule formation, which is the body’s normal reaction to any foreign object. The problem starts when that capsule thickens, contracts, and squeezes the implant into a firm, sometimes painful ball. What you can do about it depends on how far the process has progressed, ranging from medication and monitoring in mild cases to full surgical removal of the scar capsule in severe ones.

Why the Body Builds a Capsule

When any foreign material is placed in the body, the immune system responds by walling it off. Around a breast implant, the body lays down a thin layer of collagen fibers, essentially creating a pocket of scar tissue that encases the device. In most people, this capsule stays thin and pliable, and the implant looks and feels natural for years. In capsular contracture, the healing process goes off-script. Instead of settling down, the inflammatory response persists, and the cells that build scar tissue keep producing collagen long after they should have stopped.

Recent research has zeroed in on the cellular machinery behind this runaway scarring. A key player is a protein called periostin, which pushes ordinary fibroblasts to transform into myofibroblasts, cells that both produce collagen and actively contract tissue. In lab experiments, cells engineered to produce extra periostin showed dramatically higher levels of a marker for myofibroblast transformation and produced significantly more collagen than control cells.¹ In plain terms, the implant triggers inflammation, the inflammation signals fibroblasts to build scar tissue, and in some people, molecular signals like periostin keep that cycle running when it should have wound down. The result is a capsule that thickens and tightens over months or years.

Risk Factors That Make Hardening More Likely

Not everyone who gets breast implants develops noticeable capsular contracture. Several factors tilt the odds.

Bacterial Biofilm

One of the strongest theories for why capsular contracture develops involves bacteria. Even in seemingly sterile surgical fields, small numbers of bacteria can colonize the implant surface and form biofilms, thin, sticky colonies that are difficult for the immune system to clear. A study examining 45 explanted implants found that about a third of those removed for significant contracture harbored substantial bacterial growth, compared with only one in eighteen removed for other reasons.² An earlier study found bacteria on over half of implants surrounded by contracted capsules versus fewer than one in five without contracture, with Staphylococcus epidermidis as the most common organism.³ These are not the kinds of infections that cause fever or redness. They are subclinical, quietly stoking inflammation for months or years, and this chronic low-grade irritation appears to be a major driver of the fibrosis that hardens the implant.

Late-onset capsular contracture, the kind that develops six months or more after surgery, is especially associated with biofilm formation that stimulates ongoing inflammation and fibrosis.⁴

Implant Placement

Where the implant sits in the chest matters. Placing the implant beneath the pectoral muscle (subpectoral) is consistently associated with lower contracture rates compared with placing it above the muscle (prepectoral). A meta-analysis drawing on over 17,000 cases found that subpectoral placement was linked to roughly a third the odds of capsular contracture compared with prepectoral placement.⁵ The muscle layer may act as a barrier that reduces bacterial contamination from breast tissue and provides more blood supply to the pocket, both of which can dampen the inflammatory response.

Subfascial placement, where the implant goes under the fascia but above the muscle, may also offer some protection. Data suggest it has a lower contracture rate than above-the-muscle placement and may rival submuscular placement, though the evidence is still limited.⁶

Implant Surface Texture

The question of smooth versus textured implants and contracture risk is surprisingly complicated. An initial pooled analysis of over 35,000 implants found smooth implants had about 70 percent higher capsular contracture rates than textured ones. But once researchers controlled for the surgical plane and excluded overlapping datasets, the difference vanished.⁷ A separate study found smooth implants placed above the muscle (subfascial) had roughly four times the contracture risk of textured implants in the same plane, but when both were placed under the muscle, the difference disappeared.⁸ In other words, where you put the implant may matter more than what its surface looks like.

Hematoma and Surgical Complications

Bleeding after surgery that forms a hematoma around the implant raises the risk of capsular contracture. In an animal model, implants exposed to hematoma developed thick, stiff capsules graded at the highest severity levels, while non-hematoma implants stayed soft.⁹ The clinical message is straightforward: anything that causes excess bleeding, seroma, or surgical trauma in the implant pocket creates a more inflammatory environment that promotes capsule formation.¹⁰

Radiation and Genetic Predisposition

Radiation therapy to the chest, common after mastectomy for breast cancer, significantly increases the risk of capsular contracture in implant-based reconstruction.¹¹ This is one reason why reconstruction after cancer treatment tends to carry higher contracture rates than cosmetic augmentation.

There is also emerging evidence that genetics play a role. Certain immune-system gene variants, particularly in the HLA family, appear to predispose some women to exaggerated inflammatory responses to silicone. One study found that a specific HLA variant was present in over 80 percent of women with silicone-implant-associated autoimmune muscle inflammation, compared with roughly 30 percent of women with muscle inflammation unrelated to implants.¹² This line of research is still early, but it helps explain why some women develop severe contracture while others with identical implants and surgical techniques never do.

How Hardness Is Graded

Surgeons classify capsular contracture using the Baker scale, a simple four-point system. Grade I means the breast looks and feels normal. Grade II feels slightly firm but still looks natural. Grade III is visibly distorted and obviously firm to the touch. Grade IV is hard, painful, and often misshapen. Most surgeons consider Grades III and IV to warrant treatment, while Grade II is monitored but often left alone.¹³ It is worth noting that the Baker scale is subjective, based on the surgeon’s hands and eyes rather than a measurement tool, and some researchers have argued it needs updating.

Silicone Versus Saline

Silicone gel implants appear to carry a moderately higher risk of capsular contracture than saline implants. A meta-analysis found a roughly two-fold increased risk with silicone.¹⁴ Part of the explanation may be “gel bleed,” where microscopic amounts of silicone permeate through the implant shell over time. A study of different generations of silicone implants found that gel bleed correlated with capsule stiffness in a dose-dependent way: older implants with more bleed had the stiffest capsules, while newer cohesive-gel implants with minimal bleed had the softest.¹⁵ Modern cohesive gel (“gummy bear”) implants have thicker shells and more crosslinked gel that bleeds far less, which may narrow the gap between silicone and saline in newer devices.

Reducing the Risk During Surgery

Because bacterial contamination is so strongly implicated in capsular contracture, surgeons have adopted techniques designed to minimize contact between the implant and potential sources of bacteria. The “no-touch” approach uses a funnel-like delivery device (the Keller funnel) to insert the implant without it contacting the skin, which is the most common source of the staphylococcal and propionibacterial species found on contracted capsules. In one study of periareolar breast augmentations, capsular contracture rates dropped from about 10 percent to roughly 1 percent when the funnel was used.¹⁶ Most surgeons today also irrigate the implant pocket with antibiotic or antiseptic solutions before insertion, and many avoid incisions through the areola entirely when possible because the breast ducts harbor bacteria.

Non-Surgical Options for Early Contracture

If you develop mild or early-stage hardening, there are some medical options before jumping to surgery. Leukotriene receptor antagonists, medications originally developed for asthma, have shown promise in both preventing and softening early capsular contracture. Zafirlukast (sold as Accolate) appeared to effectively soften early capsular contracture in an initial study.¹⁷ A larger study of over 1,100 augmentation patients found that three months of zafirlukast after surgery significantly reduced contracture rates. Montelukast (Singulair) also showed a trend toward lower rates, though the difference did not reach statistical significance. For some patients who had already developed Grade III or IV contracture, an additional three months of medication improved the grading.¹⁸ These medications work by dampening inflammatory pathways involved in fibrosis. They are not universally adopted, but they represent one of the few non-surgical tools available.

An older technique called closed capsulotomy, where a surgeon firmly squeezes the breast to physically crack the scar capsule, was popular in the 1970s and 1980s. While it had good immediate results, the effects were short-lived and the procedure often needed to be repeated. Worse, it carried risks of implant rupture, bleeding, and silicone leakage, and it is no longer recommended.¹⁹

When Surgery Is Needed

For Baker III and IV contracture that does not respond to conservative measures, surgery is the standard treatment. The options vary in how aggressively they address the scar capsule.

Capsulotomy involves cutting into or scoring the capsule to release the constriction without removing it entirely. It provides relief but has higher recurrence rates. Capsulectomy removes the capsule, either partially (anterior capsulectomy, removing the front portion) or totally (removing the entire shell of scar tissue). A study comparing the two approaches found that recurrent contracture affected about half of patients who had only the front capsule removed, compared with roughly one in ten who had a total capsulectomy.²⁰ Most surgeons now favor total capsulectomy when feasible, often combined with changing the implant pocket (for example, moving from above the muscle to below it) to give the new implant a fresh tissue environment.

One of the more promising surgical advances involves wrapping the new implant in acellular dermal matrix (ADM), a processed tissue scaffold that integrates with the body and may prevent new scar capsule from forming around the implant. A systematic review and meta-analysis found that ADMs appear effective at treating capsular contracture with low complication rates, and that one product (Strattice) showed a statistically significant advantage over conventional treatment.²¹ A study of 100 consecutive cases concluded that adding ADM to conventional surgical techniques produced the highest success rates in capsular contracture treatment.²² Complete implant wrapping with ADM showed lower recurrence rates, though it did come with more minor complications and a somewhat higher rate of implant loss.²³

The Recurrence Problem

One of the most frustrating aspects of capsular contracture is that it tends to come back, and each time it does, the interval before the next occurrence shrinks. A retrospective study over six years found that for cosmetic augmentation patients, the average time before the first revision for contracture was about 14 years. The second revision came after about 10 years. By the third, it was roughly 7 years.²⁴ For reconstruction patients, those intervals were even shorter, starting at about 8 years and dropping to about 4. The pattern suggests that each episode of capsular contracture may prime the tissue for a faster recurrence, possibly because the inflammatory environment never fully resets to normal.

This accelerating timeline is something worth discussing with your surgeon before a first revision. If you have already had one episode of significant contracture, the question is not just how to fix it now but how to minimize the chance of repeating the cycle. That conversation might include switching to a different implant type, changing the pocket, using ADM, or even considering whether to replace the implant at all.

When Hardness Might Signal Something Else

Most of the time, a breast implant that feels hard is capsular contracture and nothing more. But there are rarer conditions that can mimic or overlap with contracture symptoms, and it is worth being aware of them.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon cancer of immune cells that develops in the fluid or capsule surrounding a breast implant, typically many years after placement. The average time between implant insertion and diagnosis is 7 to 10 years. It most often presents as a fluid collection around the implant that causes sudden swelling rather than gradual hardening, but capsule-associated masses can also occur. The main risk factor is the use of textured implants, because their rough surfaces are thought to trigger sustained local inflammation and immune stimulation that can eventually lead to abnormal lymphocyte growth.²⁵ BIA-ALCL is rare, but any sudden change in breast size, new swelling, or lump around an implant more than a year after surgery warrants prompt evaluation, typically with ultrasound and fluid analysis.

Next-Generation Implant Surfaces

The current generation of implants is not the end of the story. Researchers are working on implant surfaces designed to prevent the inflammatory cascade that leads to capsular contracture in the first place. One approach involves biomimetic coatings, surface treatments that mimic the body’s own tissue to reduce the foreign-body response. Strategies under investigation include decellularized tissue matrices applied to the implant surface and therapies targeting specific molecular pathways involved in fibrosis.²⁶

One experimental coating, a proprietary anti-inflammatory surface modification, has already shown significant reduction in capsule formation around silicone implants in laboratory testing.²⁷ These technologies are still in early stages, but they represent a fundamental shift in approach: instead of trying to treat contracture after it happens, the goal is to build implants that the body does not react against so aggressively in the first place. For people considering implants now, these developments are still years from the clinic, but they offer a reason for cautious optimism that future implants may carry a lower long-term risk of hardening.